MedTrace Logo

A Study of MG-K10 in Subjects With Asthma

NCT05382910 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-08-21

No results posted yet for this study

Summary

This study is a phase Ib/II clinical trial conducted in Chinese adult asthmatic subjects to evaluate the preliminary efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of asthma.

Conditions

Interventions

DRUG

MG-K10

MG-K10 Humanized Monoclonal Antibody Injection

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Principal Investigators

  • Nanshan Zhong, Medical PhD · The First Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-12-20
Completion
2024-06-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382910 on ClinicalTrials.gov